Study of the Association Between Hip Fracture and Acid‐Suppressive Drug Use in a UK Primary Care Setting
- 13 March 2014
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 34 (6) , 570-581
Abstract
Objectives: We aimed to clarify the nature of the association between hip fracture risk and use of proton pump inhibitors (PPIs) or histamine2‐receptor antagonists (H2RAs).Methods: We identified patients 40–89 years of age with a recorded hip fracture diagnosis in 2000–2008 using The Health Improvement Network, a UK primary care research database. Computerized records were reviewed and questionnaires sent to primary care physicians to validate hip fracture cases. A cohort study with a nested case‐control analysis was performed to estimate the association between the use of acid‐suppressive drugs and hip fracture.Results: Overall incidence of hip fracture per 1000 person‐years was 1.31 (95% confidence interval [CI] 1.28–1.33). There was a modest increased risk of hip fracture after adjustment for potential confounders (odds ratios [OR] during current use of PPIs and H2RAs: 1.09 [95% CI 1.01–1.17] and 1.04 [95% CI 0.90–1.19], respectively). Relative to nonuse, an increased risk of fracture was observed with medium and high doses of PPIs (OR 1.11 [95% CI 1.01–1.22] and OR 1.31 [95% CI 1.06–1.61], respectively) and high doses of H2RAs (OR 2.77, 95% CI 1.21–6.37). No duration response was observed (ORs for current PPI use less than 1 month and 5 years or longer: 1.16 [95% CI 0.94–1.43] and 1.02 [95% CI 0.87–1.20], respectively).Conclusions: Patients treated with PPIs showed a modest increased risk of hip fracture after adjustment for potential cofounders. Any remaining association between PPI use and hip fracture risk may be attributable to residual confounding.Keywords
Funding Information
- AstraZeneca R&D, Mölndal, Sweden
- Bayer Pharma AG, Berlin, Germany
This publication has 41 references indexed in Scilit:
- Meta-analysis: Risk of fractures with acid-suppressing medicationBone, 2011
- Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk PatientsGastroenterology, 2010
- Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control studyOsteoporosis International, 2010
- Proton Pump Inhibitor Use, Hip Fracture, and Change in Bone Mineral Density in Postmenopausal WomenArchives of internal medicine (1960), 2010
- Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonatesOsteoporosis International, 2009
- American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux DiseaseGastroenterology, 2008
- Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older AdultsCalcified Tissue International, 2008
- Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk FactorsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Long-term Proton Pump Inhibitor Therapy and Risk of Hip FractureJAMA, 2006
- Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of FractureCalcified Tissue International, 2006